API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.globenewswire.com//news-release/2023/11/01/2770950/0/en/Monopar-Presents-Data-Showing-Tumor-Reduction-Benefit-of-Camsirubicin-from-Ongoing-Phase-1b-at-the-2023-Connective-Tissue-Oncology-Society-CTOS-Annual-Meeting.html
https://www.globenewswire.com/news-release/2023/01/26/2595889/0/en/Monopar-Announces-Projected-Timeline-of-Upcoming-Q1-2023-Data-Events-for-Validive-Camsirubicin-and-MNPR-101-RIT.html
https://www.globenewswire.com/news-release/2021/09/16/2298363/0/en/Monopar-Initiates-Open-Label-Phase-1b-Clinical-Trial-Evaluating-Camsirubicin-in-Patients-with-Advanced-Soft-Tissue-Sarcoma.html
https://www.biospace.com/article/releases/monopar-announces-fda-clearance-to-proceed-with-camsirubicin-clinical-trial-targeting-advanced-soft-tissue-sarcoma/